(Q39289698)

English

Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination

scientific article published on 2 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

interpersonal psychotherapy

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Andrea Fagiolini

object named as

Andrea Fagiolini

7

0 references

9

object named as

David J Kupfer

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Paola Rucci

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Ellen Frank

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Simona Calugi

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Antonella Benvenuti

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Meredith Wallace

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Luca Maggi

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Giovanni B Cassano

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

2 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

955-962

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

The influence of cognitive variables on recovery in depressed inpatients.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

A review of empirically supported psychological therapies for mood disorders in adults

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Escitalopram: a review of its use in the management of major depressive disorder in adults

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Panic-agoraphobic spectrum: reliability and validity of assessment instruments

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

The factor structure of lifetime depressive spectrum in patients with unipolar depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

The structure of lifetime manic-hypomanic spectrum

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

The structure of lifetime panic-agoraphobic spectrum

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Treatment resistant depression--advances in somatic therapies

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Cognitive therapy in relapse prevention in depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Enhancing the efficacy of antidepressants with psychotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

21 January 2018

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Residual symptoms in depressed patients who respond acutely to fluoxetine.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year outcomes for maintenance therapies in recurrent depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year outcome for maintenance therapies in recurrent depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance treatment of major depression in old age

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring Mood Spectrum: Comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring social anxiety and obsessive-compulsive spectra: comparison of interviews and self-report instruments

1 reference

https://api.crossref.org/works/10.1002%2FDA.20894

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20894

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39289698&oldid=1818322228"